15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Iovance Biotherapeutics Inc, 5 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $4.00 to $14.00 (about 3.5x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $9.50 sits 102% above the current $4.71. The rating mix has stayed broadly stable, with Buy-side ratings easing from 7 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.12 next quarter toward $-0.32 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Moderate Buy
Strong Buy00%
Buy583%
Hold117%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Iovance Biotherapeutics Inc.
As of Jul, 5 of 6 firms rate IOVA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
IOVA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.12
Range $-0.17 – $-0.09 · 8 analysts · -51% YoY
Next period, 8 analysts expect Iovance Biotherapeutics Inc to earn $-0.12 a share (range $-0.17 – $-0.09), versus $-0.25 a year earlier. Full-year consensus is $-0.56, growing to $-0.32 the year after.
REVENUE · NEXT QUARTER
$95.8M
Range $91.7M – $102.3M · 8 analysts · +42% YoY
Revenue is expected to reach $95.8M (range $91.7M – $102.3M), +42.0% year-over-year. Full-year consensus is $362.1M, rising to $496.3M next year.
Top analysts covering Iovance Biotherapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IOVA.
#1
Geulah Livshits
Chardan Capital · Rank #100
Buy
$14.00+197.6% to target
Overall win rate
44%
+ Follow
#2
Joseph Catanzaro
Piper Sandler · Rank #219
Hold
$6.00+27.5% to target
Overall win rate
41%
+ Follow
#3
Joseph Pantginis
HC Wainwright & Co. · Rank #266
Buy
$9.00+91.3% to target
Overall win rate
32%
+ Follow
#4
Reni J. Benjamin
JMP Securities · Rank #290
Buy
$5.00+6.3% to target
Overall win rate
33%
+ Follow
#5
DD
David Dai
UBS
Hold
$4.00-15.0% to target
Coverage
—
+ Follow
IOVA stock forecast FAQ
What is IOVA's average 12-month price target?+
The 6 analysts with a live target average $9.50 for Iovance Biotherapeutics Inc over the next 12 months, ranging from a $14.00 high to a $4.00 low.
Is IOVA stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 6 analyst ratings, 5 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for IOVA?+
The Street-high target is $14.00 (Chardan Capital), and the Street-low is $4.00 (UBS). The average of all 6 active targets is $9.50.
How many Wall Street analysts cover IOVA?+
6 analysts have an active rating on Iovance Biotherapeutics Inc, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering IOVA?+
Among analysts who currently cover IOVA, Geulah Livshits of Chardan Capital has the strongest overall Quantellect track record (Rank #100). Their current call is Buy with a $14.00 target.
What is Iovance Biotherapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.12 per share (range $-0.17 – $-0.09) across 8 analysts. Full-year EPS is projected at $-0.56, rising to $-0.32 the following year.
How much revenue is Iovance Biotherapeutics Inc expected to report next quarter?+
Consensus revenue is $95.8M (range $91.7M – $102.3M). Full-year revenue is projected at $362.1M, growing to $496.3M next year.
Have analysts been upgrading or downgrading IOVA lately?+
As of Jul, 5 of 6 firms rate IOVA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IOVA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
